Apoorva Gogna
Overview
Explore the profile of Apoorva Gogna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kho Y, Lee S, Chin K, Sidek N, Ma V, Seng D, et al.
Radiographics
. 2024 May;
44(6):e230157.
PMID: 38814798
High-frequency US, with a linear transducer and gray-scale, color, and spectral Doppler US techniques, is the primary imaging modality for evaluation of the penis. It can allow delineation of anatomy...
2.
Chia A, Gogna A, Pena A, Sai V, Chandramohan S, Chan S, et al.
J Cardiothorac Surg
. 2024 Feb;
19(1):85.
PMID: 38341594
Background: Video-assisted thoracoscopic (VATS) lung resections are increasingly popular and localization techniques are necessary to aid resection. We describe our experience with hybrid operating room (OR) cone-beam computed tomography (CT)...
3.
Tan H, Tan A, Jun Teh K, Gogna A, Too C, Leong S, et al.
Sci Rep
. 2023 Oct;
13(1):16980.
PMID: 37813906
Hepatic venous pressure gradient (HVPG) is an accurate measure of portal hypertension in cirrhosis. However, the effect of catheter tip distance from hepatic vein ostium (HVO) on HVPG is unknown....
4.
Gogna A, Tan H, Too C, Chang Pik Eu J
Clin Liver Dis (Hoboken)
. 2023 Sep;
22(2):75-79.
PMID: 37663554
No abstract available.
5.
Kaya N, Tai D, Lim X, Lim J, Lau M, Goh D, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37586766
Background: Combination therapy with radioembolization (yttrium-90)-resin microspheres) followed by nivolumab has shown a promising response rate of 30.6% in a Phase II trial (CA209-678) for advanced hepatocellular carcinoma (HCC); however,...
6.
Urlings T, Gogna A, Burgmans M, Tay K, Too C, Patel A, et al.
J Endovasc Ther
. 2023 Jul;
:15266028231185506.
PMID: 37434379
Background: Current techniques to evaluate computed tomography (CT) foot perfusion in patients with critical limb ischemia use high contrast doses and cannot be used during endovascular procedures. CT perfusion of...
7.
Zhuang K, Irani F, Gogna A, Too C, Tan B, Tay K
Cardiovasc Intervent Radiol
. 2023 Jul;
46(9):1144-1153.
PMID: 37414842
Arteriovenous fistula (AVF) stenosis is a common problem leading to dialysis access dysfunction. The conventional balloon (CB) is the most commonly used device during angioplasty but suffers from poor durability...
8.
Tashi S, Gogna A, Leong S, Venkatanarasimha N, Chandramohan S
Diagn Interv Radiol
. 2023 Mar;
29(2):318-325.
PMID: 36987983
Percutaneous thermal ablation of hepatic tumors is accepted as a safe, reliable, and cost-effective therapeutic option for treating hepatocellular carcinoma and hepatic metastases. However, operators should be familiar with the...
9.
Tashi S, Tan Z, Gogna A
CVIR Endovasc
. 2022 Dec;
5(1):67.
PMID: 36562878
Learning Objective: To share our experience in utilising the triple coaxial (triaxial) system in superselective cannulation of arteries for complex embolisation procedures. Background: Percutaneous transcatheter selective embolisation is widely performed...
10.
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Lai G, Yeo J, Jain A, Zhou S, Pang M, Alvarez J, et al.
JTO Clin Res Rep
. 2022 Nov;
3(12):100416.
PMID: 36426287
Introduction: Although immune checkpoint inhibitors (ICIs) have dramatically improved outcomes for nononcogene-addicted NSCLC, monotherapy with programmed cell death protein-1 (PD1) inhibition has been associated with low efficacy in the EGFR-mutant...